Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential

Area of Science:

• Oncology
• Natural Product Chemistry
• Pharmacology

Background:

• Gastrointestinal (GI) cancers pose a significant global health challenge due to high incidence and limited treatment options.
• Carvacrol, a natural phenol from oregano, exhibits potent anticancer activities.
• Current therapeutic strategies for GI cancers often face limitations in efficacy and side effects.

Purpose of the Study:

• To review the therapeutic potential of carvacrol against various gastrointestinal (GI) cancers.
• To consolidate preclinical findings on carvacrol's anticancer mechanisms and delivery enhancements.
• To highlight the need for clinical validation of carvacrol in GI cancer management.

Main Methods:

• Literature review of preclinical studies on carvacrol's anticancer effects.
• Analysis of carvacrol's molecular targets, including apoptosis, inflammation, and angiogenesis.
• Examination of nanotechnology-based delivery systems and synergistic combinations with chemotherapy.

Main Results:

• Carvacrol demonstrates selective cytotoxicity against cancer cells, sparing healthy tissues.
• It modulates key pathways involved in cancer progression, including apoptosis, inflammation, angiogenesis, and metastasis.
• Nanotechnology enhances carvacrol's solubility, stability, and targeted delivery, while synergistic effects with chemotherapy are observed.

Conclusions:

• Carvacrol exhibits significant preclinical anticancer potential for GI malignancies.
• Nanotechnology and combination therapies may improve its clinical efficacy.
• Further clinical trials are essential to establish carvacrol as a viable therapeutic agent for GI cancers.